Swissmedic Grants Approval for IFINWIL® to Treat High-Risk Neuroblastoma in Children Norgine announces Swissmedic's approval of IFINWIL® for high-risk neuroblastoma in children, enhancing treatment options for pediatric patients.

Swissmedic Grants Approval for IFINWIL® to Treat High-Risk Neuroblastoma in Children #Switzerland #Neuroblastoma #Norgine #IFINWIL #Ubxbridge

Norgine Celebrates TGA Approval of IFINWIL® for High-Risk Neuroblastoma Patients in Australia Norgine announces the approval of IFINWIL® by Australia's TGA for treating high-risk neuroblastoma, marking a significant advancement for pediatric cancer care.

Norgine Celebrates TGA Approval of IFINWIL® for High-Risk Neuroblastoma Patients in Australia #Australia #Neuroblastoma #Norgine #IFINWIL #Ugxbridge

Norgine Celebrates TGA Approval of IFINWIL® for High-Risk Neuroblastoma Treatment in Australia Norgine announces the TGA registration of IFINWIL® for treating high-risk neuroblastoma, benefiting children and adults in Australia.

Norgine Celebrates TGA Approval of IFINWIL® for High-Risk Neuroblastoma Treatment in Australia #Australia #Neuroblastoma #Uxbridge #IFINWIL #TGA